
Validation has been a regulatory requirement for decades. The principles are well understood, guidance documents are widely available, and most organizations can recite the fundamentals with ease.
Yet validation failures remain one of the most common drivers of regulatory observations across pharmaceuticals, natural health products, medical devices, food, and other regulated sectors.
This persistence suggests a deeper issue. In most cases, validation does not fail because teams lack technical knowledge. It fails because validation is treated as a task rather than a system.
When Validation Becomes a One-Time Event
One of the most frequent causes of validation failure is timing.
Validation activities are often compressed into the final stages of development or implementation. Equipment is installed, processes are operational, and only then does validation begin. At that point, decisions have already been made, risks are embedded, and flexibility is limited.
Regulators consistently expect validation to be integrated throughout the lifecycle. User requirements, design decisions, risk assessments, and change control should all inform the validation strategy. When validation is treated as a standalone exercise, gaps inevitably surface during inspection.

Misalignment Between Risk and Effort
Another common issue is disproportionate validation.
Some systems are over-validated, with extensive testing applied to low-risk functions. Others are under-validated, particularly where legacy processes or “well understood” systems are assumed to be compliant by default.
Regulatory guidance consistently emphasizes a risk-based approach to validation. Validation effort should align with product impact, patient or consumer risk, and process complexity. When this alignment is missing, documentation may exist, but the underlying rationale is difficult to defend.
Inspectors are less concerned with the volume of testing than with whether the relevant risks were identified and addressed.
Documentation That Describes Activity, Not Control
Validation documentation often focuses on what was done rather than what was demonstrated.
Protocols may list test steps without clearly linking them to requirements. Reports may summarize results without addressing deviations or unresolved issues. Traceability between user requirements, functional specifications, and test outcomes may be incomplete or unclear.
From a regulatory perspective, validation documentation should tell a coherent story. It should explain how risks were identified, how controls were verified, and how ongoing control is maintained. When documentation reads as a record of activity rather than evidence of control, confidence erodes.
Failure to Maintain the Validated State
Even well-executed validation can fail if it is not maintained.
Changes to equipment, software, suppliers, or processes are common. What is less common is the consistent reassessment of validation impact when those changes occur. Change control systems may exist, but validation considerations are not always integrated into decision-making.
Regulators routinely assess whether organizations can demonstrate continued control over validated systems. When change histories are incomplete or rationales are undocumented, the original validation loses relevance.
Validation is not static. Regulators expect it to evolve with the system it supports.
Disconnect Between Validation, Quality, and Operations
Validation failures often reflect broader organizational silos.
Validation may be managed by engineering, quality by a separate function, and operations by another. When communication between these groups is limited, critical information is lost. Assumptions go unchallenged. Responsibilities become unclear.
Regulators assess validation within the context of the overall quality system. When validation decisions are disconnected from CAPA, deviation management, or management review, deficiencies become more apparent during inspection.

What Regulators Are Actually Assessing
During inspections, regulators do not evaluate validation in isolation. They assess whether validation supports consistent, controlled operations.
Key questions often include:
- Were risks identified early and addressed appropriately?
- Do validation activities align with intended use and product impact?
- Is documentation clear, traceable, and current?
- Is the validated state maintained through effective change control?
- Does management understand and oversee the validation strategy?
When these questions can be answered with evidence, validation findings are far less likely.
How MCS Associates Supports Effective Validation
At MCS Associates, we approach validation as an integrated component of regulatory compliance, not a documentation exercise.
We support clients by:
- Developing risk-based validation strategies aligned with regulatory expectations
- Reviewing validation documentation for traceability, clarity, and defensibility
- Assessing change control and lifecycle management of validated systems
- Identifying gaps between validation, quality systems, and operational practice
- Supporting inspection readiness and regulatory responses related to validation
Our focus is on ensuring validation activities meaningfully support product quality and regulatory confidence.
Validation Failure Is a System Signal
When validation fails, it is rarely an isolated technical issue. It is a signal that systems, communication, or governance require attention.
Organizations that treat validation as a continuous, risk-informed process are better positioned to withstand regulatory scrutiny. Those who view it as a one-time requirement often struggle to defend their approach when questioned.
At MCS Associates, we help organizations shift validation from a regulatory obligation to a strategic asset that supports compliance, operational stability, and long-term confidence. Talk to the team at MCS Associates today and see how we can help you reach compliance and maintain stability.
Resources:
- Health Canada. Good Manufacturing Practices (GMP) Guidelines.
https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices.html - Health Canada. Validation Guidelines for Pharmaceutical Processes.
https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/validation.html - U.S. Food and Drug Administration. Process Validation: General Principles and Practices.
https://www.fda.gov/media/71021/download - International Council for Harmonization (ICH). Q8, Q9, and Q10 Guidelines.
Related Posts
Enforcement Deadline for Canadian Food Labeling Transition is December 15, 2022
On December 15, 2022, CFIA will commence enforcement on food label compliance. From December 15, 2022, until December 14, Go to Article
Preparation for Preventive Control Plan (PCP) Inspections: Deviation vs Non-compliance (Part 1)
It goes without saying that if you operate a food business whether as a manufacturer, processor importer or exporter Go to Article
Food Safety Hazards Considerations for Plant-Based Meat Alternatives
The shift in consumer appetite to plant-based proteins, or meat alternatives, continues to grow in popularity as an alternative Go to Article


